Dr.ย Zhi-Mingย Shao
MBBS, Master of Oncology
Professor, Chief Physician & Director of Breast Surgery
corporate_fareFudan University Shanghai Cancer Center, Shanghai
Zhi-Ming Shao
MBBS, Master of Oncology
Prof. Zhi-Ming Shao is one of China's foremost breast cancer specialists, combining high-volume surgical practice with translational research and national oncology leadership at Fudan University Shanghai Cancer Center. With a clinical career spanning more than four decades, he is internationally recognised for his contributions to triple-negative breast cancer molecular classification, adjuvant chemotherapy optimisation, and neoadjuvant immunotherapy research.
Since 2000, Prof. Shao has served as Director of Breast Surgery at Fudan University Shanghai Cancer Center, and since 2002 as Director of the Fudan University Breast Cancer Institute. He later became Director of the Fudan University Cancer Institute and Chair of General Surgery โ placing him at the centre of patient care, multidisciplinary management, research strategy, and academic training in China. His team's work on the 'Fudan classification' of triple-negative breast cancer divides TNBC into molecular subtypes to guide individualised treatment planning. A phase III trial led by his team showed that adjuvant capecitabine improved five-year disease-free survival in triple-negative breast cancer, with results published in the Journal of Clinical Oncology. A subsequent phase III study on camrelizumab combined with neoadjuvant chemotherapy improved pathological complete response from 44.7% to 56.8% in early and locally advanced TNBC across 40 clinical centres in China.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Prof. Shao, subject to hospital availability and case acceptance.
Why Consider Prof. Zhi-Ming Shao?
Prof. Shao brings together more than four decades of breast cancer surgery, China-led clinical trial leadership, and internationally recognised expertise in triple-negative breast cancer โ offering patients access to evidence-based, precision-guided treatment planning at one of China's top academic cancer centres.
Areas of Specialisation
Precision breast oncology with a major focus on triple-negative and high-risk breast cancer
Prof. Shao's clinical and research work centres on breast cancer surgery, molecular subtyping, systemic treatment optimisation, and immunotherapy-based strategies โ particularly for triple-negative and locally advanced breast cancer.
Breast Cancer Surgery
High-volume surgical practice for early-stage, locally advanced, and complex breast cancer presentations.
- arrow_rightSurgery for early-stage and locally advanced breast cancer
- arrow_rightSurgical planning guided by molecular subtype and staging
- arrow_rightMultidisciplinary surgical decision-making within tumour board
Triple-Negative Breast Cancer
Internationally recognised expertise in one of the most aggressive and difficult-to-treat breast cancer subtypes.
- arrow_rightFudan classification of TNBC into molecular subtypes
- arrow_rightSubtype-guided personalised treatment planning
- arrow_rightMulti-omics-based clinical cohort research
- arrow_rightCamrelizumab (PD-1 inhibitor) combined with neoadjuvant chemotherapy
- arrow_rightPathological complete response optimisation for early and locally advanced TNBC
- arrow_rightPhase III trial-validated protocols
Systemic Therapy & Precision Oncology
Chemotherapy optimisation, targeted therapy, and genomics-guided treatment planning for breast cancer.
- arrow_rightCapecitabine-based adjuvant therapy validated in phase III trial (JCO)
- arrow_rightHigh-risk breast cancer chemotherapy sequencing and dose optimisation
- arrow_rightClinical sequencing using the Fudan-BC panel (1,134 breast cancers characterised)
- arrow_rightBiomarker-driven treatment selection and actionable mutation identification
- arrow_rightTargeted therapy research for breast cancer subpopulations
Procedures Performed
Surgical and systemic clinical services for breast cancer
Prof. Shao provides breast cancer surgery, systemic treatment planning, precision genomics-guided care, and second-opinion consultations at Fudan University Shanghai Cancer Center.
Breast Cancer Surgery
Complex DiseaseSurgical treatment for early-stage, locally advanced, and complex breast cancer cases.
Systemic Cancer Treatment
Medical OncologyEvidence-based chemotherapy and immunotherapy protocols for breast cancer, including high-risk and triple-negative subtypes.
Precision Oncology & Molecular Diagnostics
Targeted TherapyGenomics-guided treatment planning using clinical sequencing to identify actionable mutations and guide targeted therapy selection.
Multidisciplinary Management
MultidisciplinaryIntegrated breast cancer care combining surgery, medical oncology, radiation oncology, and translational research at a major academic cancer centre.
Second Opinion Consultations
Second OpinionIndependent expert review of pathology, molecular profiling, imaging, and treatment history for breast cancer patients.
Research & Publications
Phase III clinical trials and peer-reviewed contributions in breast cancer
Prof. Shao has authored several hundred breast cancer publications, including landmark phase III trial results published in the Journal of Clinical Oncology and studies in Nature Communications and other international journals. His team's research has contributed substantially to TNBC molecular subtyping, adjuvant chemotherapy evidence, and neoadjuvant immunotherapy protocols.
Prof. Shao has authored several hundred peer-reviewed breast cancer publications. A detailed publication list is available through Fudan University Shanghai Cancer Center or on request via CancerFax.
Education & Training
Prof. Shao completed his medical training at Shanghai Medical University and undertook postgraduate breast cancer research and training in the United States, including at Bowman Gray School of Medicine, the University of Maryland Cancer Center, and as a visiting professor at the UCLA Breast Center.
Clinical Experience
Prof. Shao has held senior leadership roles at Fudan University Shanghai Cancer Center since 1985, rising through clinical and research positions to become Director of Breast Surgery, Director of the Breast Cancer Institute, Director of General Surgery, and Director of the Cancer Institute โ positions that place him at the centre of China's most active breast cancer programme.
Languages & International
Prof. Shao's consultation languages have not been publicly confirmed. CancerFax can coordinate professional medical interpreter support for international patients.
CancerFax can coordinate professional medical interpreter support for international patients consulting at Fudan University Shanghai Cancer Center.
CancerFax can coordinate professional medical interpreter support for international patients when required.
How CancerFax Helps You Access Dr. Zhi-Ming Shao
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Zhi-Ming Shao's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Zhi-Ming Shao's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Zhi-Ming Shao before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Zhi-Ming Shao's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Zhi-Ming Shao's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Zhi-Ming Shao's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Zhi-Ming Shao
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Prof. Shao at Fudan University Shanghai Cancer Center, subject to hospital availability and case acceptance. Please submit your reports through CancerFax for an initial assessment.
Prof. Shao specialises in breast cancer, with a particular focus on triple-negative breast cancer, high-risk breast cancer, locally advanced breast cancer, and precision treatment planning for patients requiring individualised management. His team has contributed significantly to the molecular classification of triple-negative breast cancer and to China-specific clinical trial evidence for this subtype.
Submit your medical reports through CancerFax using the Send Your Reports button. The CancerFax team will review your documents, prepare a structured case summary, and coordinate the next steps with Fudan University Shanghai Cancer Center, subject to availability and case eligibility.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, molecular profiling results, imaging, and treatment history. Prof. Shao's team has extensive experience reviewing complex and high-risk breast cancer cases, including triple-negative presentations. The final consultation format and availability depend on the hospital's scheduling.
The Fudan classification refers to work by Prof. Shao's team at Fudan University Shanghai Cancer Center that categorised triple-negative breast cancer into molecular subtypes using multi-omics analysis. This subtype-based approach supports more personalised treatment planning for TNBC โ an aggressive form of breast cancer that lacks the common hormone and HER2 receptor targets, making it particularly challenging to treat.
Yes. Prof. Shao has led landmark phase III clinical trials in breast cancer, including a study on adjuvant capecitabine for triple-negative breast cancer published in the Journal of Clinical Oncology, and a neoadjuvant immunotherapy trial combining camrelizumab with chemotherapy across 40 clinical centres in China. CancerFax can provide further information about trial access where relevant.
Connect with Zhi-Ming Shao Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.